Silicon (Silica).

Silicon dioxide is a poorly soluble form that must first release orthosilicic acid, the only silicon species the gut absorbs. The pair is how formulators reason about how much silicon actually reaches circulation.

Silicon is found where new bone matrix is laid down and appears to act on the collagen and glycosaminoglycan scaffold that calcium salts then mineralise. Calcium supplies the mineral phase; silicon relates to the organic phase it deposits onto. Human trials pairing the two are limited, and observational bone density associations are associations rather than demonstrated cause.

Vitamin D governs how much calcium is absorbed and how bone remodelling is signalled, while silicon relates to matrix formation. The two act at different steps of the same process, which is the argument for their appearing together in bone formulas. No trial isolates silicon plus vitamin D against vitamin D alone.

Menaquinone-7 carboxylates osteocalcin so it binds calcium into the matrix, a step that only matters if there is matrix to bind into. Silicon is associated with that matrix stage. The pairing follows the sequence of bone formation and is not backed by a joint clinical trial.

Boron and silicon are both trace elements that form stable complexes with hydroxyl-rich biomolecules and both turn up in bone and connective tissue research. Neither has a defined human requirement. They are formulated together for that shared trace-mineral role, which is a rationale rather than a measured interaction.

Ascorbate is the required cofactor for prolyl and lysyl hydroxylase, the enzymes that hydroxylate collagen so the triple helix can form. Silicon's association is with the wider connective tissue matrix rather than with a named enzyme. Pairing them covers a settled cofactor requirement alongside a less-defined structural role.

Lysyl oxidase is a copper-dependent enzyme, and without it collagen and elastin cannot form the cross-links that give connective tissue its tensile strength. That cofactor requirement is textbook and needs no citation. Silicon appears in the same tissue context, so a connective tissue formula that includes silicon without copper leaves a defined cofactor gap.

Manganese is the cofactor for glycosyltransferases that build the glycosaminoglycan chains of proteoglycans, the ground substance of cartilage and bone matrix. Silicon has been described in the same proteoglycan fraction. The enzyme requirement is settled; the silicon link is structural association rather than a defined catalytic role.

Collagen peptides supply the glycine, proline and hydroxyproline that collagen synthesis draws on, while silicon is associated with the assembled matrix around it. Skin and nail formulas pair them for that reason. No combination trial separates the silicon contribution from the peptide contribution.

MSM supplies bioavailable sulfur, which matters for the sulfated glycosaminoglycans of connective tissue, and silicon turns up in the same tissue fraction. The two are routinely combined in hair, skin and nail products. The pairing rests on shared tissue context, not on a measured interaction.

Biotin is a carboxylase cofactor in fatty acid synthesis, which keratinocytes depend on, while silicon is associated with connective tissue structure. Hair and nail formulas stack them to cover two different layers of the same tissue. Neither ingredient's contribution has been isolated in a combined product.

Hyaluronan is the unsulfated glycosaminoglycan that holds water in the dermal matrix; silicon is reported in association with the same matrix components. Skin formulas combine them for that overlap. This is a plausible pairing with no human combination data behind it.

Zinc is required by matrix metalloproteinases and by alkaline phosphatase, both active in bone and connective tissue turnover. Silicon sits in the same tissue without a defined enzyme role. A bone or skin formula pairs them to cover a settled cofactor alongside a structural trace element.

Silicon dioxide used as a flow agent has high surface area and adsorbs small molecules and ions onto its particles. In a capsule that also carries an iron salt, that adsorption can slow dissolution of the salt in the stomach. The effect depends on the amount of silica and the tablet design rather than on any property of silicon as a nutrient.

Fumed silicon dioxide is a glidant: it coats powder particles, reduces cohesion and keeps a blend flowing into a capsule or tablet die, while magnesium stearate lubricates the die wall itself. The two do different jobs and are used together in most dry-fill products. Neither is present as a nutrient at those levels.

Enzyme powders are hygroscopic and lose activity when they pick up moisture, so silicon dioxide is added to keep them dry and free-flowing. That is the same anticaking function it serves in any powder blend. It is an excipient role, not a contribution to the enzyme activity on the label.